Skip to content

Advertisement

  • Research
  • Open Access

Acute kidney injury in intensive care unit patients: a comparison between the RIFLE and the Acute Kidney Injury Network classifications

  • 1Email author,
  • 1,
  • 1,
  • 1,
  • 2,
  • 2,
  • 2 and
  • 1
Critical Care200812:R110

https://doi.org/10.1186/cc6997

  • Received: 8 June 2008
  • Accepted: 28 August 2008
  • Published:

Abstract

Introduction

Whether discernible advantages in terms of sensitivity and specificity exist with Acute Kidney Injury Network (AKIN) criteria versus Risk, Injury, Failure, Loss of Kidney Function, End-stage Kidney Disease (RIFLE) criteria is currently unknown. We evaluated the incidence of acute kidney injury and compared the ability of the maximum RIFLE and of the maximum AKIN within intensive care unit hospitalization in predicting inhospital mortality of critically ill patients.

Methods

Patients admitted to the Department of Intensive Medicine of our hospital between January 2003 and December 2006 were retrospectively evaluated. Chronic kidney disease patients undergoing dialysis or renal transplant patients were excluded from the analysis.

Results

In total, 662 patients (mean age, 58.6 ± 19.2 years; 392 males) were evaluated. AKIN criteria allowed the identification of more patients as having acute kidney injury (50.4% versus 43.8%, P = 0.018) and classified more patients with Stage 1 (risk in RIFLE) (21.1% versus 14.7%, P = 0.003), but no differences were observed for Stage 2 (injury in RIFLE) (10.1% versus 11%, P = 0.655) and for Stage 3 (failure in RIFLE) (19.2% versus 18.1%, P = 0.672). Mortality was significantly higher for acute kidney injury defined by any of the RIFLE criteria (41.3% versus 11%, P < 0.0001; odds ratio = 2.78, 95% confidence interval = 1.74 to 4.45, P < 0.0001) or of the AKIN criteria (39.8% versus 8.5%, P < 0.0001; odds ratio = 3.59, 95% confidence interval = 2.14 to 6.01, P < 0.0001). The area under the receiver operator characteristic curve for inhospital mortality was 0.733 for RIFLE criteria (P < 0.0001) and was 0.750 for AKIN criteria (P < 0.0001). There were no statistical differences in mortality by the acute kidney injury definition/classification criteria (P = 0.72).

Conclusions

Although AKIN criteria could improve the sensitivity of the acute kidney injury diagnosis, it does not seem to improve on the ability of the RIFLE criteria in predicting inhospital mortality of critically ill patients.

Keywords

  • Acute Kidney Injury
  • Intensive Care Unit Patient
  • Chronic Kidney Disease Patient
  • Acute Kidney Injury Network
  • Acute Kidney Injury Patient

Introduction

Multiple definitions have until recently been used for acute kidney injury (AKI), and therefore the wide variation in definitions has made it difficult to compare results across studies and populations [1]. Recently, however, the Acute Dialysis Outcome Initiative group proposed a classification for AKI – the Risk, Injury, Failure, Loss of Kidney Function, and End-stage Kidney Disease (RIFLE) classification – in order to have a uniform standard for diagnosing and classifying AKI [2]. The standard defines three grades of severity – risk (Class R), injury (Class I) and failure (Class F) – and two outcome classes – loss of kidney function and end-stage kidney disease [2].

This classification system includes separate criteria for creatinine and urine output. A patient can fulfill the criteria through changes in serum creatinine or changes in urine output, or both. The criteria that lead to the worst possible classification should be used. Class R is considered if there is an increase of serum creatinine X1.5 or an urinary output < 0.5 ml/kg/hour for 6 hours; Class I is considered if there is an increase of serum creatinine X2 or an urinary output < 0.5 ml/kg/hour for 12 hours; and Class F is considered if there is an increase of serum creatinine X3, or in patients with serum creatinine >4 mg/dl if there is an acute rise in serum creatinine of at least 0.5 mg/dl, or a urinary output < 0.3 ml/kg/hour for 24 hours, or anuria for 12 hours (Table 1).
Table 1

Risk, Injury, Failure, Loss of Kidney Function, End-stage Kidney Disease classification [2]

Class

GFR criteria

Urinary output criteria

Risk

Serum creatinine × 1.5 or GFR decrease > 25%

< 0.5 ml/kg/hour × 6 hours

Injury

Serum creatinine × 2 or GFR decrease > 50%

< 0.5 ml/kg/hour × 12 hours

Failure

Serum creatinine × 3, GFR decrease > 75% or serum creatinine ≥4 mg/dl with an acute rise > 0.5 mg/dl

< 0.3 ml/kg/hour × 24 hours, or anuria × 12 hours

Loss

Persistent acute renal failure = complete loss of kidney function > 4 weeks

 

End-stage kidney disease

End-stage kidney disease > 3 months

 

For conversion of creatinine expressed in conventional units to standard units, multiply by 88.4. Patients are categorized on serum creatinine or urinary output, or both, and the criteria that lead to the worst classification are used. Glomerular filtration rate (GFR) criteria are calculated as an increase of serum creatinine above the baseline serum creatinine level. When the baseline serum creatinine is unknown and there is no past history of chronic kidney disease, serum creatinine is calculated using the Modification of Diet in Renal Disease formula for assessment of kidney function [14], assuming a GFR of 75 ml/min/1.73 m2.

Several studies have demonstrated that the RIFLE criteria have clinical relevance for the diagnosis of AKI, classifying the severity of AKI and for monitoring the progression of AKI, as well as having predictive ability for mortality in hospitalized patients in general, and patients in the intensive care unit (ICU) setting in particular [312]. Nevertheless, a more recent classification for AKI based on the RIFLE system has been proposed by the Acute Kidney Injury Network (AKIN) [13]. This new staging system (Table 2) differs from the RIFLE classification as follows: it reduces the need for baseline creatinine but does require at least two creatinine values within 48 hours; AKI is defined as an abrupt (within 48 hours) reduction in kidney function, currently defined as an absolute increase in serum creatinine ≥0.3 mg/dl (≥26.4 μmol/l), a percentage increase in serum creatinine ≥50% (1.5-fold from baseline), or a reduction in urine output (documented oliguria < 0.5 ml/kg/hour for > 6 hours); risk maps to Stage 1, but it also considers an increase in serum creatinine ≥0.3 mg/dl (≥26.4 μmol/l); injury and failure map to Stages 2 and 3, respectively; Stage 3 also includes patients who need renal replacement therapy irrespective of the stage they are in at the time of renal replacement therapy; and the two outcome classes loss and end-stage kidney disease have been removed.
Table 2

Classification/staging system for acute kidney injury [13] modified from the Risk, Injury, Failure, Loss of Kidney Function, End-stage Kidney Disease criteria [2]

Stage

Serum creatinine criteria

Urine output criteria

1

Increase in serum creatinine ≥0.3 mg/dl (≥26.4 μmol/l) or increase to ≥150% to 200% (1.5-fold to 2-fold) from baseline

< 0.5 ml/kg/hour for > 6 hours

2

Increase in serum creatinine to > 200% to 300% (> 2-fold to 3-fold) from baseline

< 0.5 ml/kg/hour for > 12 hours

3a

Increase in serum creatinine to > 300% (> 3-fold) from baseline, or serum creatinine ≥4.0 mg/dl (≥354 μmol/l) with an acute increase of at least 0.5 mg/dl (44 μmol/l)

< 0.3 ml/kg/hour for 24 hours, or anuria for 12 hours

Acute kidney injury is defined as an abrupt (within 48 hours) reduction in kidney function, currently defined as an absolute increase in serum creatinine ≥0.3 mg/dl (≥26.4 μmol/l), a percentage increase in serum creatinine ≥50% (1.5-fold from baseline), or a reduction in urine output (documented oliguria < 0.5 ml/kg/hour for > 6 hours). aIndividuals who receive renal replacement therapy are considered to have met the criteria of Stage 3 irrespective of the stage they are in at the time of renal replacement therapy.

These modifications were based on the accumulating evidence that small increases in serum creatinine are associated with adverse outcomes, and on the variability inherent in commencing renal replacement therapy and inherent to resources in different populations and countries. Despite the AKIN criteria possibly having greater sensitivity and specificity, it is currently unknown whether discernible advantages exist with one approach towards definition and classification versus the other.

In the present study, we evaluated the incidence of AKI and compared the ability of the maximum RIFLE and of the maximum AKIN within ICU hospitalization in predicting inhospital mortality of critically ill patients.

Materials and methods

The present study is retrospective, including all patients admitted to the ICU of the Hospital de Santa Maria (Lisbon, Portugal) between January 2003 and December 2006. Variables such as age, gender, race, body weight, history of cardiovascular disease (angina pectoris, myocardial infarction, cerebrovascular disease, and diabetes mellitus), primary diagnosis, Simplified Acute Physiology Score version II, vasopressor use, need for mechanical ventilation or renal replacement therapy, serum creatinine, urine output and outcome were collected from the ICU database and patient medical charts.

Baseline serum creatinine values were unavailable and were estimated by the Modification of Diet in Renal Disease equation [14], as recommended (assuming a lower limit of the normal baseline glomerular filtration rate of 75 ml/min/1.73 m2) and previously applied [2, 4, 9]. In this ICU, serum creatinine is determined at least once a day and urine output is recorded hourly, for all patients. AKI was defined and classified by means of the RIFLE criteria [2] (Table 1) and the AKIN criteria [13] (Table 2). Patients were categorized on serum creatinine or on urine output, or both, the criteria that led to the worst classification were used, and the maximum AKIN and the maximum RIFLE within ICU hospitalization were reported. At least two serum creatinine values within 48 hours were considered to define AKIN stages. The maximum RIFLE was calculated considering the maximum creatinine with reference to the Modification of Diet in Renal Disease equation-estimated creatinine, and the reference creatinine used for AKIN staging was the lowest creatinine within a 48-hour timeframe.

Sepsis was classified in accordance with the American College of Chest Physicians and the Society of Critical Care Medicine consensus [15]. The Simplified Acute Physiology Score version II was used to evaluate illness severity, and was calculated based on the worst variables recorded during the first 24 hours of ICU admission [16]. Inhospital mortality was considered the outcome measure. Chronic kidney disease patients on dialysis and renal transplant patients were excluded from the analysis. Since this was a retrospective and observational study that did not evaluate a specific therapeutic or prophylactic intervention, institutional ethical approval was not required according to our institution's guidelines.

Statistical analysis

Continuous variables are expressed as the mean ± standard deviation, and categorical variables are presented as the percentage of the number of cases. Comparisons between RIFLE classes or AKIN stages were performed using analysis of variance and the chi-square test for continuous variables and categorical variables, respectively. Multivariate logistic regression analysis was employed to evaluate the association between RIFLE criteria and AKIN criteria with inhospital mortality. Model fit was assessed by the goodness of-fit test, and discrimination was assessed by the area under the receiver operator characteristic (AuROC) curve.

Data are presented as odds ratios (ORs) with 95% confidence intervals (CIs). A two-tailed P value < 0.05 was considered significant. Analysis was performed with the statistical software package SPSS 15.0 for Windows (Produtos e Serviços de Estatísticas, Lisboa, Portugal).

Results

During the study period 703 patients were admitted to the ICU, but 41 of them were chronic kidney disease patients undergoing dialysis and were excluded from the analysis. None of the patients had received a renal transplant. A total of 662 patients (mean age, 58.6 ± 19.2 years; 392 males; 613 Caucasian; mean Simplified Acute Physiology Score version II, 46.3 ± 18.6) were therefore evaluated. Patient baseline characteristics are summarized in Tables 3 and 4.
Table 3

Patient baseline characteristics

Variable

Value

Mean age (years)

58.6 ± 19.2

Male (%)

59.2

Caucasian (%)

92.6

Mean body weight (kg)

74.2 ± 16.1

History of cardiovascular diseasea (%)

53.2

Medical admission (%)

76.4

Sepsisb (%)

40.9

Baseline serum creatinine (μmol/l)c

96.9 ± 37.2

Simplified Acute Physiology Score version IId

46.3 ± 18.6

Vasopressors (%)

40

Need for mechanical ventilation (%)

84.7

Mean length of stay (days)

8.2 ± 6.5

aAngina pectoris, myocardial infarction, cerebrovascular disease, and diabetes mellitus. bDefined in accordance with the American College of Chest Physicians and the Society of Critical Care Medicine consensus [15]. cEstimated by the Modification of Diet in Renal Disease equation [14], assuming a lower limit of the normal baseline glomerular filtration rate of 75 ml/min/1.73 m2. dCalculated based on the worst variables recorded during the first 24 hours of admission [16].

Table 4

Patient baseline characteristics and the Risk, Injury, Failure, Loss of Kidney Function, End-stage Kidney Disease (RIFLE) criteria

Variable

No acute kidney injury (n = 372)

Risk (n = 97)

Injury (n = 73)

Failure (n = 120)

P value

Mean age (years)

55 ± 19

64 ± 18

63 ± 15

61 ± 16

< 0.0001

Male (%)

55.6

65.9

63

62.5

0.252

Caucasian (%)

93

91.7

91.8

92.5

1.000

History of cardiovascular diseasea (%)

48.4

63.9

61.6

54.2

0.023

Medical admission (%)

71.8

78.4

80.8

86.7

0.008

Sepsisb (%)

26.6

39.2

61.6

74.2

< 0.0001

Baseline serum creatinine (μmol/l)c

86 ± 24

100 ± 42

107 ± 26

123 ± 50

< 0.0001

Simplified Acute Physiology Score version IId

40 ± 15

48 ± 15

51 ± 18

62 ± 21

< 0.0001

Vasopressors (%)

21.5

48.5

63

76.7

< 0.0001

Need for mechanical ventilation (%)

83.6

85.6

86.3

86.7

1.000

Urine output (l)e

2.2 ± 0.9

0.5 ± 0.2

0.9 ± 0.5

1.4 ± 1.1

 

Serum creatinine at maximum RIFLE

 

162 ± 35

235 ± 32

395 ± 54

 

Need for renal replacement therapy

     

   % of patients

 

2

12.3

56.7

< 0.0001

   Mean time (days)

5 ± 2

10 ± 8

9 ± 7

0.599

 

Mean length of stay (days)

7 ± 8

8 ± 6

9 ± 10

11 ± 12

0.009

Mortality

11

30.9

32.8

55

< 0.0001

Complete renal function recoveryf

74.6

73.5

55.6

0.053

 

aAangina pectoris, myocardial infarction, cerebrovascular disease, and diabetes mellitus. bDefined in accordance with the American College of Chest Physicians and the Society of Critical Care Medicine consensus [15]. cEstimated by the Modification of Diet in Renal Disease equation [14], assuming a lower limit of the normal baseline glomerular filtration rate of 75 ml/min/1.73 m2. dCalculated based on the worst variables recorded during the first 24 hours of admission [16]. eAt maximum RIFLE (6-hour urine output for risk, 12-hour urine output for injury, and 24-hour urine output for failure). fIf the patient returned to their baseline classification within the RIFLE criteria [2].

Acute kidney injury stratified by the RIFLE and AKIN criteria

AKI occurred in 43.8% of patients with a maximum RIFLE category: risk in 14.7%, injury in 11% and failure in 18.1% (Table 5). According to AKIN criteria, AKI occurred in 50.4% of patients – 21.1% with Stage 1, 10.1% with Stage 2 and 19.2% with Stage 3 (Table 5). AKIN criteria allowed the identification of more patients as having AKI (P = 0.018) and classified more patients with Stage 1 (risk in RIFLE) (P = 0.003); however, no statistically significant differences were observed for Stage 2 (injury in RIFLE) (P = 0.655) and for Stage 3 (failure in RIFLE) (P = 0.672).
Table 5

Incidence of acute kidney injury stratified by the Risk, Injury, Failure, Loss of Kidney Function, End-stage Kidney Disease (RIFLE) and the Acute Kidney Injury Network (AKIN) definition/classification schemes

RIFLE classification

AKIN classification

None

372 (56.2%)

None

328 (49.5%)

Risk

97 (14.7%)

Stage 1

140 (21.1%)

Injury

73 (11%)

Stage 2

67 (10.1%)

Failure

120 (18.1%)

Stage 3

127 (19.2%)

Any category

290 (43.8%)

Any stage

334 (50.4%)

Creatinine criteria led to a maximum RIFLE and a maximum AKIN in 64.1% and 67.4% of patients, respectively, whereas in almost 5% of patients it was the urine output criteria that led to a maximum RIFLE and a maximum AKIN. Creatinine and urine output criteria both led to a maximum RIFLE and a maximum AKIN in 30.3% and 27.8% of patients, respectively (Table 6).
Table 6

Patients with acute kidney injury classified by creatinine criteria or urine output criteria, or both criteria

 

Creatinine (%)

Urine output (%)

Creatinine + urine output (%)

RIFLE classification

   

   Risk

85.5

5.2

9.3

   Injury

68.5

6.8

24.7

   Failure

44.2

5

50.8

   Any category

64.1

5.6

30.3

AKIN classification

   

   Stage 1

87.1

3.6

9.3

   Stage 2

73.1

7.5

19.4

   Stage 3

42.5

4.7

52.8

   Any category

67.4

4.8

27.8

Seventy-nine AKI patients (27.2%), defined by the RIFLE classification based on creatinine and urine output criteria, received renal replacement therapy. The requirement of renal replacement therapy was higher in accordance with severity of AKI, defined by the RIFLE classification based on creatinine and urine output criteria (risk, 2%; injury; 12.3%; failure, 56.7%; P < 0.0001; AuROC curve = 0.829), and either on creatinine criteria (risk, 2%; injury, 13%; failure, 56.1%; P < 0.0001; AuROC curve = 0.818) or on urine output criteria (risk, 0%; injury, 27.5%; failure, 77.6%; P < 0.0001; AuROC curve = 0.787).

Mortality

The overall mortality was 24.3%, and mortality was significantly higher for AKI patients as compared with non-AKI patients, as follows: AKI defined by any of the RIFLE criteria (41.3% versus 11%, P < 0.0001; OR = 2.78, 95% CI = 1.74 to 4.45, P < 0.0001) or AKIN criteria (39.8% versus 8.5%, P < 0.0001; OR = 3.59, 95% CI = 2.14 to 6.01, P < 0.0001) (Tables 7 and 8).
Table 7

Mortality according to acute kidney injury stratified by the Risk, Injury, Failure, Loss of Kidney Function, End-stage Kidney Disease (RIFLE) and the Acute Kidney Injury Network (AKIN) definition/classification schemes

RIFLE classification

AKIN classification

None

11%

None

8.5%

Risk

30.9%

Stage 1

30.7%

Injury

32.8%

Stage 2

32.8%

Failure

55%

Stage 3

53.5%

Any category

41.3%

Any stage

39.8%

Table 8

Separate multivariate regression analysis for the Risk, Injury, Failure, Loss of Kidney Function, End-stage Kidney Disease (RIFLE) and the Acute Kidney Injury Network (AKIN) classifications

Criteria

Hospital mortality (odds ratio (95% confidence interval))

P value

Area under receiver operator characteristic curve

RIFLE criteria (creatinine + urine output)

   

   Risk

2.69 (1.49 to 4.88)

0.001

0.733

   Injury

2.01 (1.03 to 3.89)

0.038

 

   Failure

3.59 (2.01 to 6.42)

< 0.0001

 

   Any category

2.78 (1.74 to 4.45)

< 0.0001

 

AKIN criteria (creatinine + urine output)

   

   Stage 1

3.54 (1.97 to 6.37)

< 0.0001

0.750

   Stage 2

2.71 (1.33 to 5.53)

0.006

 

   Stage 3

4.66 (2.49 to 8.73)

< 0.0001

 

   Any stage

3.59 (2.14 to 6.01)

< 0.0001

 

RIFLE criteria (creatinine)

   

   Risk

2.63 (1.46 to 4.75)

0.001

0.729

   Injury

2.12 (1.1 to 4.08)

0.025

 

   Failure

3.2 (1.8 to 5.7)

< 0.0001

 

   Any category

2.68 (1.69 to 4.25)

< 0.0001

 

AKIN criteria (creatinine)

   

   Stage 1

3.18 (1.79 to 5.64)

< 0.0001

0.745

   Stage 2

2.74 (1.35 to 5.56)

0.005

 

   Stage 3

3.93 (2.12 to 7.28)

< 0.0001

 

   Any stage

3.38 (2.05 to 5.57)

< 0.0001

 

RIFLE criteria (urine output)

   

   Risk

1.3 (0.35 to 4.8)

0.689

0.619

   Injury

0.83 (0.31 to 2.21)

0.711

 

   Failure

3.26 (1.74 to 6.13)

< 0.0001

 

   Any category

2.06 (1.24 to 3.42)

0.005

 

AKIN criteria (urine output)

   

   Stage 1

1.03 (0.3 to 3.58)

0.953

0.612

   Stage 2

1.03 (0.35 to 2.99)

0.953

 

   Stage 3

2.65 (1.45 to 4.84)

0.001

 

   Any stage

1.9 (1.16 to 3.14)

0.01

 

Defined by both creatinine and urine output criteria or by creatinine criteria or by urine output criteria, including age, gender, race, history of cardiovascular disease, medical admission, sepsis diagnosis, illness severity evaluated by Simplified Acute Physiology Score version II, and need for vasopressors or for mechanical ventilation.

The analysis was repeated using the RIFLE or AKIN classification either based only on creatinine criteria or only on urine output criteria. AKI defined by any of the criteria was associated with mortality (RIFLE creatinine, OR = 2.68, 95% CI = 1.69 to 4.25, P < 0.0001; AKIN creatinine, OR = 3.38, 95% CI = 2.05 to 5.57, P < 0.0001; RIFLE urine output, OR = 2.06, 95% CI = 1.24 to 3.42, P = 0.005; AKIN urine output, OR = 1.9, 95% CI = 1.16 to 3.14, P = 0.01). RIFLE classes and AKIN stages based on creatinine criteria predicted mortality – whereas when the maximum RIFLE and the maximum AKIN were based on urine output criteria, only Class F and Stage 3 were independently associated with mortality (Table 8).

When considering both creatinine and urine output criteria, the AuROC curve for inhospital mortality was 0.733 for RIFLE criteria (P < 0.0001) and 0.750 for AKIN criteria (P < 0.0001) (Figures 1 and 2). There were no statistically significant differences in mortality by the AKI definition/classification criteria (P = 0.72).
Figure 1
Figure 1

Area under the receiver operator characteristic (AuROC) curve for inhospital mortality for the Risk, Injury, Failure, Loss of Kidney Function, End-stage Kidney Disease criteria (P < 0.0001).

Figure 2
Figure 2

Area under the receiver operator characteristic (AuROC) curve for inhospital mortality for the Acute Kidney Injury Network criteria (P < 0.0001).

The AuROC curve for inhospital mortality was 0.729 for RIFLE creatinine (P < 0.0001) and was 0.745 for AKIN creatinine (P < 0.0001), whereas the AuROC curve was 0.619 (P < 0.0001) for RIFLE urine output and was 0.612 for AKIN urine output (P < 0.0001).

Discussion

We conducted a single-center study with 662 ICU patients to compare the new recently released definitions/classifications for AKI – the RIFLE system and the AKIN system.

We confirmed that the RIFLE system allows the identification and classification of a significant proportion of ICU patients as having some degree of AKI, and predicts inhospital mortality. These findings have also been reported in a variety of ICU patients [3, 512].

Nevertheless, a more recent classification for AKI based on the RIFLE system has been proposed by the AKIN workgroup [13]. This new staging system differs from RIFLE as follows: it reduces the need for a baseline creatinine value but does require at least two creatinine values within 48 hours; AKI is defined as an abrupt (within 48 hours) reduction in kidney function, currently defined as an absolute increase in serum creatinine ≥0.3 mg/dl (≥26.4 μmol/l), a percentage increase in serum creatinine ≥50% (1.5-fold from baseline), or a reduction in urine output (documented oliguria < 0.5 ml/kg/hour for > 6 hours); risk maps to Stage 1, but it also considers an increase in serum creatinine ≥0.3 mg/dl (≥26.4 μmol/l); injury and failure map to Stages 2 and 3, respectively; Stage 3 also includes patients who need renal replacement therapy irrespective of the stage they are in at the time of renal replacement therapy; and the two outcome classes loss and end-stage kidney disease have been removed. These modifications were based on the accumulating evidence that small increases in serum creatinine are associated with adverse outcomes, and on the variability inherent in commencing renal replacement therapy and inherent to resources in different populations and countries. Despite the AKIN system possibly having greater sensitivity and specificity, it is currently unknown whether discernible advantages exist with one approach towards definition and classification versus the other.

In the present study, despite AKIN criteria allowing the identification of 6.6% more patients (50.4% versus 43.8%, P = 0.018) as having some degree of AKI and increasing the number of patients classified as Stage 1 (risk in RIFLE) (from 14.7% to 21.1%, P = 0.003), no statistically significant differences in terms of inhospital mortality were found according to AKI definition/classification criteria. In a recent report Bagshaw and colleagues utilized a large multicenter (120,123 patients, 57 ICUs) clinical database and found no statistically significant differences in terms of incidence of AKI and inhospital mortality by the RIFLE criteria or the AKIN criteria in the first 24 hours after admission [17]. These observations suggest that the proposed modifications for the RIFLE classification, the most widely used definition of acute renal failure in both the critical care and nephrology literature [18], do not improve the ability of this classification in predicting inhospital mortality of ICU patients.

As suggested by a North East Italian multicenter study on AKI, classified by the RIFLE criteria, in 2,164 ICU patients [19], in our analysis the serum creatinine criteria seemed to be a better predictor of mortality than urine output. In fact, a rise in creatinine is an earlier sign of worsening renal function than oliguria. In > 60% of our patients with AKI, the creatinine criteria led to a worse RIFLE class or AKIN stage than urine output.

The current study has some limitations. First, it is a single-center and retrospective study with a relatively small cohort of patients. Second, we did not know the baseline serum creatinine level or the prevalence of chronic kidney disease (except for those undergoing dialysis). Instead, we calculated an estimate of baseline function using the Modification of Diet in Renal Disease equation, as recommended (assuming a lower limit of the normal baseline glomerular filtration rate of 75 ml/min) and previously applied [2, 4, 9]. Third, despite having hourly records of urine output, we did not have data regarding additional factors that could influence urine output such as diuretic therapy. Overall, we recognize that any biases would influence both the RIFLE criteria and the AKIN criteria, and thus would not significantly influence our conclusions.

Despite these limitations our study has several strengths. First, it is the second study comparing the incidence of AKI, defined by the RIFLE criteria and the AKIN criteria, and the prognostic ability of these classifications in ICU patients. Second, the creatinine criteria and urine output criteria were both used to define and categorize AKI. Finally, we did not limit our analysis to the first 24 hours of ICU admission, contrary to Bagshaw and colleagues [17].

Conclusion

In summary, our results suggest that although the AKIN criteria could improve the sensitivity of the AKI diagnosis, they do not improve on the ability of the RIFLE criteria in predicting inhospital mortality of critically ill patients. Taking into consideration the extensive validation of the RIFLE criteria in a higher number of patients and heterogeneous groups of patients and cohorts than any other widely accepted and applied definitions and classifications for AKI [2022], it is time for the utilization of the RIFLE criteria in randomized controlled clinical trials as a surrogate marker of clinically important outcome to establish specific interventions for prevention or attenuation of AKI.

Key messages

  • The RIFLE criteria allowed the identification of 43.8% of ICU patients as having some degree of AKI.

  • The AKIN criteria could improve the sensitivity of the AKI diagnosis but do not improve on the ability of the RIFLE criteria in predicting inhospital mortality of ICU patients.

Abbreviations

AKI: 

acute kidney injury

AKIN: 

Acute Kidney Injury Network

AuROC: 

area under the receiver operator characteristic

CI: 

confidence interval

ICU: 

intensive care unit

OR: 

odds ratio

RIFLE: 

Risk, Injury, Failure, Loss of Kidney Function, End-stage Kidney Disease.

Declarations

Authors’ Affiliations

(1)
Department of Nephrology and Renal Transplantation, Hospital de Santa Maria, Av. Prof. Egas Moniz, Lisboa, 1649-035, Portugal
(2)
Department of Intensive Medicine, Hospital de Santa Maria, Av. Prof. Egas Moniz, Lisboa, 1649-035, Portugal

References

  1. Bellomo R, Kellum JA, Ronco C: Defining acute renal failure: physiological principles. Intensive Care Med 2004, 30: 33-37. 10.1007/s00134-003-2078-3View ArticlePubMedGoogle Scholar
  2. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, Acute Dialysis Quality Initiative workgroup: Acute renal failure – definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004, 8: R204-R212. 10.1186/cc2872PubMed CentralView ArticlePubMedGoogle Scholar
  3. Hoste EA, Clermont G, Kersten A, Venkataraman R, Angus DC, De Bacquer D, Kellum JA: RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis. Crit Care 2006, 10: R73-R82. 10.1186/cc4915PubMed CentralView ArticlePubMedGoogle Scholar
  4. Uchino S, Bellomo R, Goldsmith D, Bates S, Ronco C: An assessment of the RIFLE criteria for acute renal failure in hospitalized patients. Crit Care Med 2006, 34: 1913-1917. 10.1097/01.CCM.0000224227.70642.4FView ArticlePubMedGoogle Scholar
  5. Ahlstrom A, Kuitunen A, Peltonen S, Hynninen M, Tallgren M, Aaltonen J, Pettilä V: Comparison of 2 acute renal failure severity scores to general scoring systems in the critically ill. Am J Kidney Dis 2006, 48: 262-268. 10.1053/j.ajkd.2006.04.086View ArticlePubMedGoogle Scholar
  6. Lopes JA, Jorge S, Silva S, de Almeida E, Abreu F, Martins C, do Carmo JA, Lacerda JF, Prata MM: An assessment of the RIFLE criteria for acute renal failure following myeloablative autologous and allogeneic haematopoietic cell transplantation. Bone Marrow Transplant 2006, 38: 395. [letter] 10.1038/sj.bmt.1705461View ArticlePubMedGoogle Scholar
  7. Kuitunen A, Vento A, Suojaranta-Ylinen R, Pettilä V: Acute renal failure after cardiac surgery: evaluation of the RIFLE classification. Ann Thorac Surg 2006, 81: 542-546. 10.1016/j.athoracsur.2005.07.047View ArticlePubMedGoogle Scholar
  8. Lin CY, Chen YC, Tsai FC, Tian YC, Jenq CC, Fang JT, Yang CW: RIFLE classification is predictive of short-term prognosis in critically ill patients with acute renal failure supported by extracorporeal membrane oxygenation. Nephrol Dial Transplant 2006, 21: 2867-2873. 10.1093/ndt/gfl326View ArticlePubMedGoogle Scholar
  9. Guitard J, Cointault O, Kamar N, Muscari F, Lavayssière L, Suc B, Ribes D, Esposito L, Barange K, Durand D, Rostaing L: Acute renal failure following liver transplantation with induction therapy. Clin Nephrol 2006, 65: 103-112.View ArticlePubMedGoogle Scholar
  10. O'Riordan A, Wong V, McQuillan R, McCormick PA, Hegarty JE, Watson AJ: Acute renal disease, as defined by the RIFLE criteria, post-liver transplantation. Am J Transplant 2007, 7: 168-176. 10.1111/j.1600-6143.2006.01602.xView ArticlePubMedGoogle Scholar
  11. Ostermann M, Chang RW: Acute kidney injury in the intensive care unit according to RIFLE. Crit Care Med 2007, 35: 1837-1843. 10.1097/01.CCM.0000277041.13090.0AView ArticlePubMedGoogle Scholar
  12. Lopes JA, Jorge S, Neves FC, Caneira M, da Costa AG, Ferreira AC, Prata MM: An assessment of the rifle criteria for acute renal failure in severely burned patients. Nephrol Dial Transplant 2007, 22: 285. [letter] 10.1093/ndt/gfl468View ArticlePubMedGoogle Scholar
  13. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A, Acute Kidney Injury Network: Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007, 11: R31. 10.1186/cc5713PubMed CentralView ArticlePubMedGoogle Scholar
  14. Manjunath G, Sarnak MJ, Levey AS: Prediction equations to estimate glomerular filtration rate: an update. Curr Opin Nephrol Hypertens 2001, 10: 785-792. 10.1097/00041552-200111000-00009View ArticlePubMedGoogle Scholar
  15. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G, SCCM/ESICM/ACCP/ATS/SIS: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003, 4: 1250-1256. 10.1097/01.CCM.0000050454.01978.3BView ArticleGoogle Scholar
  16. Le Gall JR, Lemeshow S, Saulnier F: A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 1993, 270: 2957-2963. 10.1001/jama.270.24.2957View ArticlePubMedGoogle Scholar
  17. Bagshaw SM, George C, Bellomo R, for the ANZICS Database Management Committee: A comparison of the RIFLE and AKIN criteria for acute kidney injury in critically ill patients. Nephrol Dial Transplant 2008, 23: 1569-1574. 10.1093/ndt/gfn009View ArticlePubMedGoogle Scholar
  18. Kellum JA, Bellomo R, Ronco C: Classification of acute kidney injury using RIFLE: what's the purpose? Crit Care Med 2007, 35: 1983-1984. 10.1097/01.CCM.0000277518.67114.F8View ArticlePubMedGoogle Scholar
  19. Cruz DN, Bolgan I, Perazella MA, Bonello M, de Cal M, Corradi V, Polanco N, Ocampo C, Nalesso F, Piccinni P, Ronco C, for the North East Italian Prospective Hospital Renal Outcome Survey on Acute Kidney Injury (NEiPHROS-AKI) Investigators: North East Italian Prospective Hospital Renal Outcome Survey on Acute Kidney Injury (NEiPHROS-AKI): targeting the problem with the RIFLE criteria. Clin J Am Soc Nephrol 2007, 2: 418-425. 10.2215/CJN.03361006View ArticlePubMedGoogle Scholar
  20. Bellomo R, Kellum JA, Ronco C: Defining and classifying acute renal failure: from advocacy to consensus and validation of the RIFLE criteria. Intensive Care Med 2007, 33: 409-413. 10.1007/s00134-006-0478-xView ArticlePubMedGoogle Scholar
  21. Ricci Z, Cruz D, Ronco C: The RIFLE criteria and mortality in acute kidney injury: a systematic review. Kidney Int 2008, 73: 538-546. 10.1038/sj.ki.5002743View ArticlePubMedGoogle Scholar
  22. Hoste EA, Schurgers M: Epidemiology of acute kidney injury: how big is the problem? Crit Care Med 2008, 36: S146-S151. 10.1097/CCM.0b013e318168c590View ArticlePubMedGoogle Scholar

Copyright

© Lopes et al.; licensee BioMed Central Ltd. 2008

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement